153 related articles for article (PubMed ID: 38202655)
1. Rivastigmine-Bambuterol Hybrids as Selective Butyrylcholinesterase Inhibitors.
Wu J; Tan Z; Pistolozzi M; Tan W
Molecules; 2023 Dec; 29(1):. PubMed ID: 38202655
[TBL] [Abstract][Full Text] [Related]
2. Identification of Compounds for Butyrylcholinesterase Inhibition.
Li S; Li AJ; Travers J; Xu T; Sakamuru S; Klumpp-Thomas C; Huang R; Xia M
SLAS Discov; 2021 Dec; 26(10):1355-1364. PubMed ID: 34269114
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis and biological evaluation of novel carbamates as potential inhibitors of acetylcholinesterase and butyrylcholinesterase.
Wu J; Pistolozzi M; Liu S; Tan W
Bioorg Med Chem; 2020 Mar; 28(5):115324. PubMed ID: 32008882
[TBL] [Abstract][Full Text] [Related]
4. Amino acid residues involved in the interaction of acetylcholinesterase and butyrylcholinesterase with the carbamates Ro 02-0683 and bambuterol, and with terbutaline.
Kovarik Z; Radić Z; Grgas B; Skrinjarić-Spoljar M; Reiner E; Simeon-Rudolf V
Biochim Biophys Acta; 1999 Aug; 1433(1-2):261-71. PubMed ID: 10446376
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis and biological evaluation of bambuterol analogues as novel inhibitors of butyrylcholinesterase.
Wu J; Tian Y; Wang S; Pistolozzi M; Jin Y; Zhou T; Roy G; Xu L; Tan W
Eur J Med Chem; 2017 Jan; 126():61-71. PubMed ID: 27744187
[TBL] [Abstract][Full Text] [Related]
6. Butyrylcholinesterase Protein Ends in the Pathogenesis of Alzheimer's Disease-Could
Jasiecki J; Wasąg B
Biomolecules; 2019 Oct; 9(10):. PubMed ID: 31601022
[No Abstract] [Full Text] [Related]
7. Tailored Modeling of Rivastigmine Derivatives as Dual Acetylcholinesterase and Butyrylcholinesterase Inhibitors for Alzheimer's Disease Treatment.
Adeowo FY; Oyetunji TP; Ejalonibu MA; Ndagi U; Kumalo HM; Lawal MM
Chem Biodivers; 2021 Nov; 18(11):e2100361. PubMed ID: 34547176
[TBL] [Abstract][Full Text] [Related]
8. Stereoselective inhibition of human, mouse, and horse cholinesterases by bambuterol enantiomers.
Bosak A; Gazić I; Vinković V; Kovarik Z
Chem Biol Interact; 2008 Sep; 175(1-3):192-5. PubMed ID: 18582854
[TBL] [Abstract][Full Text] [Related]
9. Interaction of human butyrylcholinesterase variants with bambuterol and terbutaline.
Kovarik Z; Simeon-Rudolf V
J Enzyme Inhib Med Chem; 2004 Apr; 19(2):113-7. PubMed ID: 15449725
[TBL] [Abstract][Full Text] [Related]
10. Discovery of Novel Pyrazolopyrimidinone Derivatives as Phosphodiesterase 9A Inhibitors Capable of Inhibiting Butyrylcholinesterase for Treatment of Alzheimer's Disease.
Yu YF; Huang YD; Zhang C; Wu XN; Zhou Q; Wu D; Wu Y; Luo HB
ACS Chem Neurosci; 2017 Nov; 8(11):2522-2534. PubMed ID: 28783948
[TBL] [Abstract][Full Text] [Related]
11. Amino acid residues involved in stereoselective inhibition of cholinesterases with bambuterol.
Bosak A; Gazić I; Vinković V; Kovarik Z
Arch Biochem Biophys; 2008 Mar; 471(1):72-6. PubMed ID: 18167304
[TBL] [Abstract][Full Text] [Related]
12. Bis-Amiridines as Acetylcholinesterase and Butyrylcholinesterase Inhibitors:
Makhaeva GF; Kovaleva NV; Boltneva NP; Rudakova EV; Lushchekina SV; Astakhova TY; Serkov IV; Proshin AN; Radchenko EV; Palyulin VA; Korabecny J; Soukup O; Bachurin SO; Richardson RJ
Molecules; 2022 Feb; 27(3):. PubMed ID: 35164325
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis, biological evaluation, and molecular modeling studies of chalcone-rivastigmine hybrids as cholinesterase inhibitors.
Wang L; Wang Y; Tian Y; Shang J; Sun X; Chen H; Wang H; Tan W
Bioorg Med Chem; 2017 Jan; 25(1):360-371. PubMed ID: 27856236
[TBL] [Abstract][Full Text] [Related]
14. Stereoselective inhibition of human butyrylcholinesterase by the enantiomers of bambuterol and their intermediates.
Pistolozzi M; Du H; Wei H; Tan W
Drug Metab Dispos; 2015 Mar; 43(3):344-52. PubMed ID: 25504505
[TBL] [Abstract][Full Text] [Related]
15. Apigenin-rivastigmine hybrids as multi-target-directed liagnds for the treatment of Alzheimer's disease.
Sang Z; Wang K; Shi J; Cheng X; Zhu G; Wei R; Ma Q; Yu L; Zhao Y; Tan Z; Liu W
Eur J Med Chem; 2020 Feb; 187():111958. PubMed ID: 31865014
[TBL] [Abstract][Full Text] [Related]
16. Rivastigmine is a potent inhibitor of acetyl- and butyrylcholinesterase in Alzheimer's plaques and tangles.
Eskander MF; Nagykery NG; Leung EY; Khelghati B; Geula C
Brain Res; 2005 Oct; 1060(1-2):144-52. PubMed ID: 16212945
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis, and evaluation of novel cinnamic acid-tryptamine hybrid for inhibition of acetylcholinesterase and butyrylcholinesterase.
Ghafary S; Ghobadian R; Mahdavi M; Nadri H; Moradi A; Akbarzadeh T; Najafi Z; Sharifzadeh M; Edraki N; Moghadam FH; Amini M
Daru; 2020 Dec; 28(2):463-477. PubMed ID: 32372339
[TBL] [Abstract][Full Text] [Related]
18. In silico and in vitro studies confirm Ondansetron as a novel acetylcholinesterase and butyrylcholinesterase inhibitor.
Gholami A; Minai-Tehrani D; Eriksson LA
Sci Rep; 2023 Jan; 13(1):643. PubMed ID: 36635365
[TBL] [Abstract][Full Text] [Related]
19. Bambuterol, a carbamate ester prodrug of terbutaline, as inhibitor of cholinesterases in human blood.
Tunek A; Svensson LA
Drug Metab Dispos; 1988; 16(5):759-64. PubMed ID: 2906603
[TBL] [Abstract][Full Text] [Related]
20. Nature-based molecules combined with rivastigmine: A symbiotic approach for the synthesis of new agents against Alzheimer's disease.
Nesi G; Chen Q; Sestito S; Digiacomo M; Yang X; Wang S; Pi R; Rapposelli S
Eur J Med Chem; 2017 Dec; 141():232-239. PubMed ID: 29031070
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
